{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T17:21:54Z","timestamp":1793899314970,"version":"4.8.0"},"reference-count":57,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","valueinhealthjournal.com","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1016\/j.jval.2017.12.014","type":"journal-article","created":{"date-parts":[[2018,2,8]],"date-time":"2018-02-08T00:39:56Z","timestamp":1518050396000},"page":"874-880","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Medical Treatments for Acromegaly: A Systematic Review and Network Meta-Analysis"],"prefix":"10.1016","volume":"21","author":[{"given":"Let\u00edcia P.","family":"Leonart","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinicius L.","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernanda S.","family":"Tonin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Fernandez-Llimos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Pontarolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jval.2017.12.014_bib1","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1172\/JCI39375","article-title":"Acromegaly pathogenesis and treatment","volume":"119","author":"Melmed","year":"2009","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jval.2017.12.014_bib2","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1530\/EJE-16-0117","article-title":"Acromegaly incidence, prevalence, complications and long-term prognosis: a nationwide cohort study","volume":"175","author":"Dal","year":"2016","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.jval.2017.12.014_bib3","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.endonu.2016.03.009","article-title":"Epidemiology of acromegaly in Ecuador","volume":"63","author":"Lopez Gavilanez","year":"2016","journal-title":"Endocrinol Nutr"},{"key":"10.1016\/j.jval.2017.12.014_bib4","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1007\/s11102-015-0701-2","article-title":"Incidence and prevalence of acromegaly in a large US health plan database","volume":"19","author":"Burton","year":"2016","journal-title":"Pituitary"},{"key":"10.1016\/j.jval.2017.12.014_bib5","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1517\/13543784.2016.1142530","article-title":"Perspectives on investigational drugs for acromegaly","volume":"25","author":"Stormann","year":"2016","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.jval.2017.12.014_bib6","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1210\/er.2002-0022","article-title":"Systemic complications of acromegaly: epidemiology, pathogenesis, and management","volume":"25","author":"Colao","year":"2004","journal-title":"Endocr Rev"},{"key":"10.1016\/j.jval.2017.12.014_bib7","doi-asserted-by":"crossref","first-page":"3933","DOI":"10.1210\/jc.2014-2700","article-title":"Acromegaly: an endocrine society clinical practice guideline","volume":"99","author":"Katznelson","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jval.2017.12.014_bib8","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1590\/S0004-27302011000900011","article-title":"Recommendations of Neuroendocrinology Department from Brazilian Society of Endocrinology and Metabolism for diagnosis and treatment of acromegaly in Brazil","volume":"55","author":"Vieira Neto","year":"2011","journal-title":"Arq Bras Endocrinol Metabol"},{"key":"10.1016\/j.jval.2017.12.014_bib9","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s12020-015-0853-x","article-title":"Pros and cons in endocrine practice: pre-surgical treatment with somatostatin analogues in acromegaly","volume":"52","author":"Losa","year":"2016","journal-title":"Endocrine"},{"key":"10.1016\/j.jval.2017.12.014_bib10","doi-asserted-by":"crossref","first-page":"R59","DOI":"10.1530\/EC-15-0064","article-title":"Need for improved monitoring in patients with acromegaly","volume":"4","author":"Silverstein","year":"2015","journal-title":"Endocr Connect"},{"key":"10.1016\/j.jval.2017.12.014_bib11","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1080\/14656566.2016.1199687","article-title":"Current and future medical treatments for patients with acromegaly","volume":"17","author":"Maffezzoni","year":"2016","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.jval.2017.12.014_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18549\/PharmPract.2017.01.943","article-title":"Network meta-analysis: a technique to gather evidence from direct and indirect comparisons","volume":"15","author":"Tonin","year":"2017","journal-title":"Pharm Pract (Granada)"},{"key":"10.1016\/j.jval.2017.12.014_bib13","unstructured":"Higgins J, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. 2011. Available from: http:\/\/handbook.cochrane.org. Access date: 07\/16\/2017"},{"key":"10.1016\/j.jval.2017.12.014_bib14","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jclinepi.2009.06.005","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"62","author":"Moher","year":"2009","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.jval.2017.12.014_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: Is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.jval.2017.12.014_bib16","doi-asserted-by":"crossref","first-page":"e003111","DOI":"10.1136\/bmjopen-2013-003111","article-title":"Methods used to conduct and report Bayesian mixed treatment comparisons published in the medical literature: a systematic review","volume":"3","author":"Sobieraj","year":"2013","journal-title":"BMJ Open"},{"key":"10.1016\/j.jval.2017.12.014_bib17","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.jval.2011.01.011","article-title":"Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices, Part 2","volume":"14","author":"Hoaglin","year":"2011","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2017.12.014_bib18","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.jval.2011.04.002","article-title":"Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices, Part 1","volume":"14","author":"Jansen","year":"2011","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2017.12.014_bib19","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/1741-7015-11-159","article-title":"Is network meta-analysis as valid as standard pairwise meta-analysis? It all depends on the distribution of effect modifiers","volume":"11","author":"Jansen","year":"2013","journal-title":"BMC Med"},{"key":"10.1016\/j.jval.2017.12.014_bib20","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/sim.3767","article-title":"Checking consistency in mixed treatment comparison meta-analysis","volume":"29","author":"Dias","year":"2010","journal-title":"Stat Med"},{"key":"10.1016\/j.jval.2017.12.014_bib21","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/jrsm.1044","article-title":"Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies","volume":"3","author":"Higgins","year":"2012","journal-title":"Res Synth Methods"},{"key":"10.1016\/j.jval.2017.12.014_bib22","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.dss.2012.10.005","article-title":"ADDIS: a decision support system for evidence-based medicine","volume":"55","author":"van Valkenhoef","year":"2013","journal-title":"Decis Support Syst"},{"key":"10.1016\/j.jval.2017.12.014_bib23","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1046\/j.0300-0664.2001.01438.x","article-title":"Long-term effects of lanreotide SR and octreotide LAR on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly","volume":"56","author":"Amato","year":"2002","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.jval.2017.12.014_bib24","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1007\/BF03349830","article-title":"Effect of 4 weeks of octreotide treatment on prolactin, thyroid stimulating hormone and thyroid hormones in acromegalic patients: a double blind placebo-controlled cross-over study","volume":"18","author":"Andersen","year":"1995","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.jval.2017.12.014_bib25","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1111\/j.1365-2265.2007.03067.x","article-title":"A 12-month randomized crossover study on the effects of lanreotide autogel and octreotide long-acting repeatable on GH and IGF-l in patients with acromegaly","volume":"68","author":"Andries","year":"2008","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.jval.2017.12.014_bib26","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1210\/jc.2013-2480","article-title":"Pasireotide versus octreotide in acromegaly: a head-to-head superiority study","volume":"99","author":"Colao","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jval.2017.12.014_bib27","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1007\/BF03345774","article-title":"Comparison of pegvisomant and long-acting octreotide in patients with acromegaly naive to radiation and medical therapy","volume":"32","author":"Ghigo","year":"2009","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.jval.2017.12.014_bib28","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1210\/jcem-70-5-1254","article-title":"A randomized study of SMS 201-995 versus bromocriptine treatment in acromegaly: clinical and biochemical effects","volume":"70","author":"Halse","year":"1990","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jval.2017.12.014_bib29","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/j.1365-2265.1994.tb02552.x","article-title":"Body composition in active acromegaly during treatment with octreotide: a double-blind, placebo-controlled cross-over study","volume":"41","author":"Hansen","year":"1994","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.jval.2017.12.014_bib30","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1046\/j.1365-2265.2000.01168.x","article-title":"Optimal dosage interval for depot somatostatin analogue therapy in acromegaly requires individual titration","volume":"53","author":"Jenkins","year":"2000","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.jval.2017.12.014_bib31","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s11102-009-0191-1","article-title":"Rapid and sustained reduction of serum growth hormone and insulin-like growth factor-1 in patients with acromegaly receiving lanreotide autogel therapy: a randomized, placebo-controlled, multicenter study with a 52 week open extension","volume":"13","author":"Melmed","year":"2010","journal-title":"Pituitary"},{"key":"10.1016\/j.jval.2017.12.014_bib32","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1056\/NEJM200004203421604","article-title":"Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant","volume":"342","author":"Trainer","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jval.2017.12.014_bib33","doi-asserted-by":"crossref","first-page":"4003","DOI":"10.1210\/jc.2014-2900","article-title":"Surgical interventions and medical treatments in treatment-naive patients with acromegaly: systematic review and meta-analysis","volume":"99","author":"Abu Dabrh","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jval.2017.12.014_bib34","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1210\/jc.2007-1191","article-title":"Mortality in acromegaly: a metaanalysis","volume":"93","author":"Dekkers","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jval.2017.12.014_bib35","doi-asserted-by":"crossref","first-page":"4465","DOI":"10.1210\/jc.2005-0260","article-title":"Long-acting somatostatin analog therapy of acromegaly: a meta-analysis","volume":"90","author":"Freda","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jval.2017.12.014_bib36","doi-asserted-by":"crossref","first-page":"e36411","DOI":"10.1371\/journal.pone.0036411","article-title":"Meta-analysis on the effects of octreotide on tumor mass in acromegaly","volume":"7","author":"Giustina","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jval.2017.12.014_bib37","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1210\/jc.2006-2547","article-title":"Impact of somatostatin analogs on the heart in acromegaly: a metaanalysis","volume":"92","author":"Maison","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jval.2017.12.014_bib38","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1007\/s11102-009-0169-z","article-title":"Effects of lanreotide SR and autogel on tumor mass in patients with acromegaly: a systematic review","volume":"13","author":"Mazziotti","year":"2010","journal-title":"Pituitary"},{"key":"10.1016\/j.jval.2017.12.014_bib39","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1007\/s11102-014-0602-9","article-title":"Preoperative somatostatin analogues versus direct transsphenoidal surgery for newly-diagnosed acromegaly patients: a systematic review and meta-analysis using the GRADE system","volume":"18","author":"Nunes","year":"2015","journal-title":"Pituitary"},{"key":"10.1016\/j.jval.2017.12.014_bib40","doi-asserted-by":"crossref","first-page":"e61523","DOI":"10.1371\/journal.pone.0061523","article-title":"Place of preoperative treatment of acromegaly with somatostatin analog on surgical outcome: a systematic review and meta-analysis","volume":"8","author":"Pita-Gutierrez","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jval.2017.12.014_bib41","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1210\/jc.2010-2443","article-title":"Place of cabergoline in acromegaly: a meta-analysis","volume":"96","author":"Sandret","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jval.2017.12.014_bib42","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.braindev.2014.04.009","article-title":"Preoperative somatostatin analogs treatment in acromegalic patients with macroadenomas: a meta-analysis","volume":"37","author":"Zhang","year":"2015","journal-title":"Brain Dev"},{"key":"10.1016\/j.jval.2017.12.014_bib43","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1472-6823-9-20","article-title":"Clinical effectiveness and cost-effectiveness of pegvisomant for the treatment of acromegaly: a systematic review and economic evaluation","volume":"9","author":"Moore","year":"2009","journal-title":"BMC Endocr Disord"},{"issue":"Suppl. 1","key":"10.1016\/j.jval.2017.12.014_bib44","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1530\/EJE-09-0350","article-title":"The German ACROSTUDY: past and present","volume":"161","author":"Buchfelder","year":"2009","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.jval.2017.12.014_bib45","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s11102-015-0691-0","article-title":"Safety of long-term treatment with pegvisomant: analysis of Spanish patients included in global ACROSTUDY","volume":"19","author":"Bernabeu","year":"2016","journal-title":"Pituitary"},{"key":"10.1016\/j.jval.2017.12.014_bib46","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.ando.2015.10.003","article-title":"Pegvisomant treatment in patients with acromegaly in clinical practice: the French ACROSTUDY","volume":"76","author":"Chanson","year":"2015","journal-title":"Ann Endocrinol (Paris)"},{"key":"10.1016\/j.jval.2017.12.014_bib47","doi-asserted-by":"crossref","first-page":"264","DOI":"10.4158\/EP14330.OR","article-title":"Long-term treatment with pegvisomant as monotherapy in patients with acromegaly: experience from ACROSTUDY","volume":"21","author":"Freda","year":"2015","journal-title":"Endocr Pract"},{"key":"10.1016\/j.jval.2017.12.014_bib48","first-page":"479","article-title":"Experience with pegvisomant treatment in acromegaly in a single Brazilian tertiary reference center: efficacy, safety and predictors of response. Arch","volume":"60","author":"Kasuki","year":"2016","journal-title":"Endocrinol Metab"},{"key":"10.1016\/j.jval.2017.12.014_bib49","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1056\/NEJMra1510061","article-title":"Adaptive designs for clinical trials","volume":"375","author":"Bhatt","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jval.2017.12.014_bib50","first-page":"1","article-title":"Challenges of developing and conducting clinical trials in rare disorders","volume":"16","author":"Kempf","year":"2017","journal-title":"Am J Med Genet A"},{"key":"10.1016\/j.jval.2017.12.014_bib51","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/bcp.12150","article-title":"Overview of methods for comparing the efficacies of drugs in the absence of head-to-head clinical trial data","volume":"77","author":"Kim","year":"2014","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jval.2017.12.014_bib52","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S2213-8587(14)70169-X","article-title":"Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial","volume":"2","author":"Gadelha","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jval.2017.12.014_bib53","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1210\/jc.2009-2272","article-title":"Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trial","volume":"95","author":"Petersenn","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jval.2017.12.014_bib54","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1002\/jcph.326","article-title":"Pharmacokinetics, pharmacodynamics, and safety of pasireotide LAR in patients with acromegaly: a randomized, multicenter, open-label, phase I study","volume":"54","author":"Petersenn","year":"2014","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.jval.2017.12.014_bib55","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1210\/jc.2011-2508","article-title":"Long-term safety of pegvisomant in patients with acromegaly: comprehensive review of 1288 subjects in ACROSTUDY","volume":"97","author":"van der Lely","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jval.2017.12.014_bib56","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1007\/s12020-014-0393-9","article-title":"ACROSTUDY: the Italian experience","volume":"48","author":"Grottoli","year":"2015","journal-title":"Endocrine"},{"key":"10.1016\/j.jval.2017.12.014_bib57","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.jclinepi.2010.02.005","article-title":"CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials","volume":"63","author":"Schulz","year":"2010","journal-title":"J Clin Epidemiol"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301518300032?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301518300032?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,30]],"date-time":"2019-06-30T22:18:31Z","timestamp":1561933111000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301518300032"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":57,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["S1098301518300032"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2017.12.014","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Medical Treatments for Acromegaly: A Systematic Review and Network Meta-Analysis","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2017.12.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}